158 related articles for article (PubMed ID: 35479283)
1. Cost-effectiveness of Direct Oral Anticoagulant vs. Warfarin Among Atrial Fibrillation Patients With Intermediate Stroke Risk.
Choi JH; Kim W; Kim YT; Cho J; Shin SY; Kim C; Kim JB
Front Cardiovasc Med; 2022; 9():849474. PubMed ID: 35479283
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.
Hernandez I; Smith KJ; Zhang Y
Thromb Res; 2017 Feb; 150():123-130. PubMed ID: 27771008
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness Analysis of Direct Oral Anticoagulants Vs. Vitamin K Antagonists in the Elderly With Atrial Fibrillation: Insights From the Evidence in a Real-World Setting.
Wu Y; Zhang C; Gu ZC
Front Cardiovasc Med; 2021; 8():675200. PubMed ID: 34268343
[No Abstract] [Full Text] [Related]
4. Anticoagulation Therapy for Atrial Fibrillation in Patients With Alzheimer's Disease.
Ruiz Vargas E; Sposato LA; Lee SAW; Hachinski V; Cipriano LE
Stroke; 2018 Dec; 49(12):2844-2850. PubMed ID: 30571418
[TBL] [Abstract][Full Text] [Related]
5. Economic Evaluation of Direct Oral Anticoagulants Compared to Warfarin for Venous Thromboembolism in Thailand: A Cost-Utility Analysis.
Niyomsri S; Nimworapan M; Wongcharoen W; Dilokthornsakul P
Int J Environ Res Public Health; 2023 Feb; 20(4):. PubMed ID: 36833871
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan.
Liu CY; Chen HC
Clin Drug Investig; 2017 Mar; 37(3):285-293. PubMed ID: 27988835
[TBL] [Abstract][Full Text] [Related]
7. [Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation].
Rudakova AV; Tatarskiĭ BA
Kardiologiia; 2014; 54(7):43-52. PubMed ID: 25177813
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation.
Hallinen T; Soini E; Asseburg C; Linna M; Eloranta P; Sintonen S; Kosunen M
Clinicoecon Outcomes Res; 2021; 13():745-755. PubMed ID: 34413661
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients.
Shah A; Shewale A; Hayes CJ; Martin BC
Stroke; 2016 Jun; 47(6):1555-61. PubMed ID: 27103018
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding.
Rattanachotphanit T; Limwattananon C; Waleekhachonloet O; Limwattananon P; Sawanyawisuth K
Pharmacoeconomics; 2019 Feb; 37(2):279-289. PubMed ID: 30387074
[TBL] [Abstract][Full Text] [Related]
11. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis.
López-López JA; Sterne JAC; Thom HHZ; Higgins JPT; Hingorani AD; Okoli GN; Davies PA; Bodalia PN; Bryden PA; Welton NJ; Hollingworth W; Caldwell DM; Savović J; Dias S; Salisbury C; Eaton D; Stephens-Boal A; Sofat R
BMJ; 2017 Nov; 359():j5058. PubMed ID: 29183961
[No Abstract] [Full Text] [Related]
12. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
[TBL] [Abstract][Full Text] [Related]
13. Updating the Cost Effectiveness of Oral Anticoagulants for Patients with Atrial Fibrillation Based on Varying Stroke and Bleed Risk Profiles.
Wang CY; Pham PN; Thai TN; Brown JD
Pharmacoeconomics; 2020 Dec; 38(12):1333-1343. PubMed ID: 32924092
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease.
Lopes RD; Steffel J; Di Fusco M; Keshishian A; Luo X; Li X; Masseria C; Hamilton M; Friend K; Gupta K; Mardekian J; Pan X; Baser O; Jones WS
Am J Med; 2018 Sep; 131(9):1075-1085.e4. PubMed ID: 29807001
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for atrial fibrillation in Portugal.
Costa J; Fiorentino F; Caldeira D; Inês M; Lopes Pereira C; Pinheiro L; Vaz-Carneiro A; Borges M; Gouveia M
Rev Port Cardiol; 2015 Dec; 34(12):723-37. PubMed ID: 26616542
[TBL] [Abstract][Full Text] [Related]
16. Selecting the right anticoagulant for stroke prevention in atrial fibrillation.
Kundnani NR; Rosca CI; Sharma A; Tudor A; Rosca MS; Nisulescu DD; Branea HS; Mocanu V; Crisan DC; Buzas DR; Morariu S; Lighezan DF
Eur Rev Med Pharmacol Sci; 2021 Jul; 25(13):4499-4505. PubMed ID: 34286492
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients.
Walter E; Voit M; Eichhober G
Expert Rev Pharmacoecon Outcomes Res; 2021 Apr; 21(2):265-275. PubMed ID: 32700584
[TBL] [Abstract][Full Text] [Related]
18. Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.
Rahme E; Godin R; Nedjar H; Dasgupta K; Tagalakis V
Thromb Res; 2021 Jul; 203():121-130. PubMed ID: 34000493
[TBL] [Abstract][Full Text] [Related]
19. Directly Acting Oral Anticoagulants for the Prevention of Stroke in Atrial Fibrillation in England and Wales: Cost-Effectiveness Model and Value of Information Analysis.
Thom HHZ; Hollingworth W; Sofat R; Wang Z; Fang W; Bodalia PN; Bryden PA; Davies PA; Caldwell DM; Dias S; Eaton D; Higgins JPT; Hingorani AD; Lopez-Lopez JA; Okoli GN; Richards A; Salisbury C; Savović J; Stephens-Boal A; Sterne JAC; Welton NJ
MDM Policy Pract; 2019; 4(2):2381468319866828. PubMed ID: 31453363
[No Abstract] [Full Text] [Related]
20. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.
Harrington AR; Armstrong EP; Nolan PE; Malone DC
Stroke; 2013 Jun; 44(6):1676-81. PubMed ID: 23549134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]